Show simple item record

dc.contributor.authorHowell, Anthony
dc.contributor.authorCuzick, Jack
dc.contributor.authorBaum, Michael
dc.contributor.authorBuzdar, Aman
dc.contributor.authorDowsett, Mitch
dc.contributor.authorForbes, John F
dc.contributor.authorHoctin-Boes, G
dc.contributor.authorHoughton, Joan
dc.contributor.authorLocker, Gershon
dc.contributor.authorTobias, J S
dc.date.accessioned2009-08-06T12:16:03Z
dc.date.available2009-08-06T12:16:03Z
dc.date.issued2005-01
dc.identifier.citationResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer., 365 (9453):60-2 Lanceten
dc.identifier.issn1474-547X
dc.identifier.pmid15639680
dc.identifier.doi10.1016/S0140-6736(04)17666-6
dc.identifier.urihttp://hdl.handle.net/10541/76533
dc.description.abstractThe standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Antagonistsen
dc.subjectCancer Metastasisen
dc.subjectCancer Recurrenceen
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAromatase Inhibitors
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDisease-Free Survival
dc.subject.meshEstrogen Antagonists
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNitriles
dc.subject.meshPostmenopause
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSurvival Rate
dc.subject.meshTamoxifen
dc.subject.meshTriazoles
dc.titleResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, UK. anthony.howell@christie-tr.nwest.nhs.uken
dc.identifier.journalLanceten
html.description.abstractThe standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record